Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study

Table 5 Cost-effectiveness analysis for hypoglycemic events and utility outcomes

	Trial arms
	BIAsp 30 (n = 82)	NPH/Reg (n = 82)
Hypoglycemia event per person-year	20.08 ± 5.60	50.76 ± 11.50
Mean difference of QALY (EQ-5D-3 L)	0.12 ± 0.05	0.04 ± 0.02
Mean difference of QALY (VAS)	0.14 ± 0.06	0.05 ± 0.04
Costs (USD)	930.55 ± 81.43	1101.24 ± 165.49
ICER	Dominant	---

Abbreviations: BIAsp biphasic insulin aspart 30, NPH/Reg NPH plus regular human insulin, QALY quality adjusted life year, EQ-5D-3 L European quality of life-5 dimensions -3 levels, VAS and visual analogue scale, USD U.S. dollars, ICER incremental cost-effectiveness ratio

ISSN: 1472-6823